Radiology:2018版LI-RADS鉴别肝细胞肝癌与其他肝脏恶性肿瘤的价值

2019-09-20 shaosai MedSci原创

本研究旨在评价2018版LI-RADS鉴别肝硬化患者和别肝细胞肝癌(HCC)与其他肝脏恶性肿瘤(OM)的价值。

本研究旨在评价2018版LI-RADS鉴别肝硬化患者和别肝细胞肝癌(HCC)与其他肝脏恶性肿瘤(OM)的价值。

本研究共纳入了55例未治疗的OM合并肝硬化的患者,对照组包括165例未行治疗的肝细胞肝癌合并肝硬化的患者。由两名放射科医生在未知最终诊断结果的情况下评价LR-M征象及主要HCC征象(动脉期非环形强化,非外周廓清及增强囊壁)。利用广义估计方程法计算并比较每个征象、LR-M标准(可能或肯定恶性,但并非为HCC)和LR-5标准(肯定为恶性)的诊断能力。

结果为,单独LRM征象诊断OM的敏感性和特异性分别为9%-71%、83%-97%。HCC典型征象诊断HCC的敏感性和特异性分别为62%-83%、69%-89%。LR-M标准诊断OM的敏感性和特异性分别为89% (95% confidence interval [CI]: 81%, 97%)、48% (95% CI: 40%, 56%)。LR-5标准诊断HCC的敏感性和特异性分别为74% (95% CI: 67%, 81%)、89% (95% CI: 81%, 97%)。LR-5标准的准确性要高于LR-M,分别为 (78% [95% CI: 72%, 83%] vs 58% [95% CI: 52%, 65%], P <. 001)。。

本研究表明,LR-5和LR-M均能够鉴别合并肝硬化的肝细胞肝癌和其他肝脏恶性肿瘤。

原始出处:

Kim YY, Kim MJ, Kim EH,et al.Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018.Radiology.DOI:10.1148/radiol.2019181995

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746780, encodeId=6d3c1e467800e, content=<a href='/topic/show?id=a4e2108e086' target=_blank style='color:#2F92EE;'>#LI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10870, encryptionId=a4e2108e086, topicName=LI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65a635842372, createdName=zhanfl, createdTime=Sat Dec 07 07:30:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029523, encodeId=b990202952392, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Mon Aug 03 17:30:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863454, encodeId=eef6186345415, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Feb 20 03:30:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792991, encodeId=80be1e929913e, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Feb 18 14:30:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597904, encodeId=67fa159e9047f, content=<a href='/topic/show?id=08d68144090' target=_blank style='color:#2F92EE;'>#肝脏恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81440, encryptionId=08d68144090, topicName=肝脏恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24ba18571401, createdName=chenlianhui, createdTime=Sun Sep 22 08:30:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040223, encodeId=c3121040223a3, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Sep 20 20:30:00 CST 2019, time=2019-09-20, status=1, ipAttribution=)]
    2019-12-07 zhanfl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746780, encodeId=6d3c1e467800e, content=<a href='/topic/show?id=a4e2108e086' target=_blank style='color:#2F92EE;'>#LI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10870, encryptionId=a4e2108e086, topicName=LI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65a635842372, createdName=zhanfl, createdTime=Sat Dec 07 07:30:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029523, encodeId=b990202952392, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Mon Aug 03 17:30:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863454, encodeId=eef6186345415, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Feb 20 03:30:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792991, encodeId=80be1e929913e, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Feb 18 14:30:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597904, encodeId=67fa159e9047f, content=<a href='/topic/show?id=08d68144090' target=_blank style='color:#2F92EE;'>#肝脏恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81440, encryptionId=08d68144090, topicName=肝脏恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24ba18571401, createdName=chenlianhui, createdTime=Sun Sep 22 08:30:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040223, encodeId=c3121040223a3, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Sep 20 20:30:00 CST 2019, time=2019-09-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746780, encodeId=6d3c1e467800e, content=<a href='/topic/show?id=a4e2108e086' target=_blank style='color:#2F92EE;'>#LI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10870, encryptionId=a4e2108e086, topicName=LI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65a635842372, createdName=zhanfl, createdTime=Sat Dec 07 07:30:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029523, encodeId=b990202952392, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Mon Aug 03 17:30:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863454, encodeId=eef6186345415, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Feb 20 03:30:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792991, encodeId=80be1e929913e, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Feb 18 14:30:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597904, encodeId=67fa159e9047f, content=<a href='/topic/show?id=08d68144090' target=_blank style='color:#2F92EE;'>#肝脏恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81440, encryptionId=08d68144090, topicName=肝脏恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24ba18571401, createdName=chenlianhui, createdTime=Sun Sep 22 08:30:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040223, encodeId=c3121040223a3, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Sep 20 20:30:00 CST 2019, time=2019-09-20, status=1, ipAttribution=)]
    2020-02-20 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=1746780, encodeId=6d3c1e467800e, content=<a href='/topic/show?id=a4e2108e086' target=_blank style='color:#2F92EE;'>#LI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10870, encryptionId=a4e2108e086, topicName=LI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65a635842372, createdName=zhanfl, createdTime=Sat Dec 07 07:30:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029523, encodeId=b990202952392, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Mon Aug 03 17:30:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863454, encodeId=eef6186345415, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Feb 20 03:30:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792991, encodeId=80be1e929913e, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Feb 18 14:30:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597904, encodeId=67fa159e9047f, content=<a href='/topic/show?id=08d68144090' target=_blank style='color:#2F92EE;'>#肝脏恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81440, encryptionId=08d68144090, topicName=肝脏恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24ba18571401, createdName=chenlianhui, createdTime=Sun Sep 22 08:30:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040223, encodeId=c3121040223a3, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Sep 20 20:30:00 CST 2019, time=2019-09-20, status=1, ipAttribution=)]
    2020-02-18 江川靖瑶
  5. [GetPortalCommentsPageByObjectIdResponse(id=1746780, encodeId=6d3c1e467800e, content=<a href='/topic/show?id=a4e2108e086' target=_blank style='color:#2F92EE;'>#LI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10870, encryptionId=a4e2108e086, topicName=LI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65a635842372, createdName=zhanfl, createdTime=Sat Dec 07 07:30:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029523, encodeId=b990202952392, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Mon Aug 03 17:30:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863454, encodeId=eef6186345415, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Feb 20 03:30:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792991, encodeId=80be1e929913e, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Feb 18 14:30:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597904, encodeId=67fa159e9047f, content=<a href='/topic/show?id=08d68144090' target=_blank style='color:#2F92EE;'>#肝脏恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81440, encryptionId=08d68144090, topicName=肝脏恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24ba18571401, createdName=chenlianhui, createdTime=Sun Sep 22 08:30:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040223, encodeId=c3121040223a3, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Sep 20 20:30:00 CST 2019, time=2019-09-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1746780, encodeId=6d3c1e467800e, content=<a href='/topic/show?id=a4e2108e086' target=_blank style='color:#2F92EE;'>#LI-RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10870, encryptionId=a4e2108e086, topicName=LI-RADS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65a635842372, createdName=zhanfl, createdTime=Sat Dec 07 07:30:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029523, encodeId=b990202952392, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Mon Aug 03 17:30:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863454, encodeId=eef6186345415, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Feb 20 03:30:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792991, encodeId=80be1e929913e, content=<a href='/topic/show?id=6d7e150911e' target=_blank style='color:#2F92EE;'>#RADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15091, encryptionId=6d7e150911e, topicName=RADS)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Feb 18 14:30:00 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597904, encodeId=67fa159e9047f, content=<a href='/topic/show?id=08d68144090' target=_blank style='color:#2F92EE;'>#肝脏恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81440, encryptionId=08d68144090, topicName=肝脏恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24ba18571401, createdName=chenlianhui, createdTime=Sun Sep 22 08:30:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040223, encodeId=c3121040223a3, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Sep 20 20:30:00 CST 2019, time=2019-09-20, status=1, ipAttribution=)]
    2019-09-20 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0